Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for EVRYSDIⓇ (risdiplam) for the treatment of adults and children with spinal muscular atrophy (SMA)

Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for EVRYSDI® (risdiplam), a pre-mRNA splicing modifier of survival of motor neuron 2 (SMN2) designed to treat SMA, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.1

NewsCatherine LamontagneFebruary 21, 2022Roche Canada, pCPA

Roche Canada Launches Data Science Coalition to Advance COVID-19 Solutions

Roche Canada is pleased to announce the launch of the Roche Data Science Coalition, a group of like-minded public and private organizations committed to working with the global community to develop solutions to the challenges of the COVID-19 pandemic. The collaborators in the Coalition include: Alberta Machine Intelligence Institute (Amii), doc.ai, NVIDIA, Self Care Catalysts, ThinkData Works Inc and Vector Institute.

NewsGuest UserApril 16, 2020COVID19, Coronavirus, Roche Canada, coalition